Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Logothetis

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
Medicine|September 13, 2021
The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progressionIoanna Maria Grypari, Souzana Logotheti, Vasiliki Zolota, et al.
Applied Bioinformatics|May 8, 2004
TAD: a web interface and database for tissue microarraysKevin R Coombes, Lin Zhang, Carlos Bueso-Ramos, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Cancer Biology & Therapy|November 20, 2008
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesisChun Chui Tsao, Bin T Teh, Eric Jonasch, et al.
Pathology|December 23, 2019
Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progressionVasiliki Tzelepi, Souzana Logotheti, Eleni Efstathiou, et al.
Genome Biology|July 8, 2020
Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencingNaveen Ramesh, Emi Sei, Pei Ching Tsai, et al.
Journal of the National Cancer Institute|March 20, 2003
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastasesHisanori Uehara, Sun Jin Kim, Takashi Karashima, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 6, 2004
Combined laser capture microdissection and serial analysis of gene expression from human tissue samplesJeong Hee Cho-Vega, Patricia Troncoso, Kim-Anh Do, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
Medicine|September 13, 2021
The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progressionIoanna Maria Grypari, Souzana Logotheti, Vasiliki Zolota, et al.
Applied Bioinformatics|May 8, 2004
TAD: a web interface and database for tissue microarraysKevin R Coombes, Lin Zhang, Carlos Bueso-Ramos, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Cancer Biology & Therapy|November 20, 2008
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesisChun Chui Tsao, Bin T Teh, Eric Jonasch, et al.
Pathology|December 23, 2019
Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progressionVasiliki Tzelepi, Souzana Logotheti, Eleni Efstathiou, et al.
Genome Biology|July 8, 2020
Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencingNaveen Ramesh, Emi Sei, Pei Ching Tsai, et al.
Journal of the National Cancer Institute|March 20, 2003
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastasesHisanori Uehara, Sun Jin Kim, Takashi Karashima, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 6, 2004
Combined laser capture microdissection and serial analysis of gene expression from human tissue samplesJeong Hee Cho-Vega, Patricia Troncoso, Kim-Anh Do, et al.
Pageof 9